

DOCON TECHNOLOGIES PRIVATE LIMITED

August 17, 2026

To, National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051	To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001
To, Thyrocare Technologies Limited D37/3, TTC MIDC, Turbhe, Navi Mumbai – 400 073	

Sub: Release of Pledge on 7,94,69,696 Equity Shares of Thyrocare Technologies Limited ("Thyrocare")

Ref: Disclosures pursuant to Regulations 29(2), 31(2) and Regulation 31(3) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir & Madam,

We refer to our earlier disclosures dated September 24, 2025, November 11, 2025, December 05, 2025, March 31, 2026, April 20, 2026 and August 13, 2026 made under Regulations 29(2) and 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("SEBI SAST Regulations"), in relation to the encumbrance created by Docon Technologies Private Limited ("Docon"), Promoter of Thyrocare Technologies Limited (the "Company"/"Thyrocare"), pursuant to the Corporate Guarantee extended by Docon to secure the obligations of API Holdings Limited ("API"), the Holding Company, in respect of facilities availed by API through the issuance of unlisted, unrated, secured, redeemable, Non-Convertible Debentures ("NCDs").

In connection with the aforesaid NCDs, Docon had pledged its equity shares of Thyrocare in favour of Catalyst Trusteeship Limited, acting as the Debenture Trustee.

The aforesaid NCDs, having an outstanding principal amount of INR 10,500 million, have been fully redeemed and repaid by API on August 14, 2026.

Consequently, upon the full redemption and repayment of the aforesaid NCDs, the pledge created by Docon over the remaining 7,94,69,696 equity shares of Thyrocare in favour of Catalyst Trusteeship Limited, acting as the Debenture Trustee, has been fully released.


Accordingly, as on August 17, 2026, **the entire pledge created by Docon over its shareholding in equity shares of Thyrocare in connection with the aforesaid NCDs stands fully released.** Further, there is no outstanding pledge or other encumbrance by the promoter over the share capital of Thyrocare.

Pursuant to Regulations 29(2), 31(2) and 31(3) of the SEBI SAST Regulations, please find enclosed the requisite disclosures:

1. Disclosure under Regulation 29(2) of the SEBI (SAST) Regulations – **Annexure I**
2. Disclosure under Regulations 31(2) and 31(3) of the SEBI (SAST) Regulations – **Annexure II**

You are requested to take the above disclosure on record.

For Docon Technologies Private Limited


Madhuri Sudhir Sarangdhar
Company Secretary



DOCON TECHNOLOGIES PRIVATE LIMITED

Annexure I

Disclosures under Regulation 29(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Thyrocare Technologies Limited ('Thyrocare')		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Acquirer: "Docon Technologies Private Limited PAC: API Holdings Limited		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. BSE Limited 2. National Stock Exchange of India Limited		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share /voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of:			
a. Shares carrying voting rights	17,30,304	1.09	1.08
b. Shares in the nature of encumbrance (pledge /lien/ non disposal undertaking/ others)	7,94,69,696	49.93	49.79
c. Voting rights (VR) otherwise than by shares	NIL	NIL	NIL
d. Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	NIL	NIL	NIL
e. Total (a+b+c+d)	8,12,00,000	51.02	50.87
Details of acquisition/sale			
a. Shares carrying voting rights acquired/sold	Nil	Nil	Nil
b. VRs acquired /sold otherwise than by shares	Nil	Nil	Nil
c. Warrants/convertible securities/any other	Nil	Nil	Nil
d. instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)- acquired/sold Shares encumbered /- invoked/released by the acquirer)	7,94,69,696	49.93	49.79
e. Total (a+b+c+/-d)	7,94,69,696	49.93	49.79

DOCON TECHNOLOGIES PRIVATE LIMITED

After the acquisition/sale, holding of:			
a. Shares carrying voting rights	8,12,00,000	51.02	50.87
b. Shares encumbered with the acquirer	Nil	Nil	Nil
c. VRs otherwise than by shares	Nil	Nil	Nil
d. Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	Nil	Nil	Nil
e. Total (a+b+c+d)	8,12,00,000	51.02	50.87
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Release of pledge over 7,94,69,696 equity shares of Thyrocare Technologies Limited held by Docon Technologies Private Limited (Promoter of Thyrocare Technologies Limited), which had been pledged in favour of Catalyst Trusteeship Limited in connection with the Non-Convertible Debentures ("NCDs") issued by API Holdings Limited.		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	August 17, 2026 (Release of Pledge)		
Equity share capital / total voting capital of the TC before the said acquisition / sale	15,91,65,315 Equity shares having face value of Rs. 10 each		
Equity share capital/ total voting capital of the TC after the said acquisition / sale	15,91,65,315 Equity shares having face value of Rs. 10 each		
Total diluted share/voting capital of the TC after the said acquisition	15,96,30,252 equity shares having face value of Rs. 10 each		

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Docon has not acquired any additional equity shares pursuant to the release of the pledge. The release of the pledge was pursuant to the full repayment of the NCDs by API. The repayment of the NCDs was funded, inter alia, through the sale of 1,57,69,696 equity shares of the Company held by Docon and through internal accruals of API.

For and on behalf of **Docon Technologies Private Limited**

Madhuri
Madhuri Sudhir Sarangdhar
 Company Secretary



Date: August 17, 2026